A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwN… (NCT07483268) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) .
China600 participantsStarted 2026-06
Plain-language summary
This study is a open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with CRSwNP.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.
* Physician decision to treat the participant with Stapokibart Injection for CRSwNP (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Exclusion Criteria:
* Known history of allergic reaction to Stapokibart Injection.
* Participants currently or plan participating in any interventional clinical trial.
* Participants with hematologic malignancies.
* Women with pregnant.
* Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
What they're measuring
1
The incidence rate of adverse reactions (ADR).
Timeframe: From enrollment to the end of treatment at 52 weeks